Abstract
There are limited data on cardiovascular efficacy and safety of type 2 diabetes therapies in Japan, where treatments are characterized by lower metformin use and higher dipeptidyl peptidase-4 inhibitor (DPP4i) use versus other countries. We investigated the cardiovascular outcomes in Japanese patients with type 2 diabetes initiating sodium-glucose cotransporter 2 inhibitors (SGLT2i) matched 1:1 to patients initiating other glucose-lowering drugs (33,890 patients/group) or DPP4i (9,876 patients/group). SGLT2i initiation was associated with lower risks (hazard ratio of in-hospital death [death] 0.56, 95% confidence interval [CI] 0.47-0.67; hospitalization for heart failure 0.75, 95% CI 0.64-0.89; composite of hospitalization for heart failure or death 0.65, 95% CI 0.58-0.74 and stroke 0.66, 95% CI 0.52-0.84 versus other glucose-lowering drugs and lower risks of death 0.52, 95% CI 0.36-0.73) and composite of hospitalization for heart failure or death (0.65, 95% CI 0.51-0.83) versus DPP4i. In conclusion, SGLT2i initiators had lower risks of cardiovascular events versus other glucose-lowering drug initiators and, uniquely, versus DPP4i initiators in Japanese real-world practice.
References
Jan 28, 2003·Diabetes Care·M WoodwardUNKNOWN Asia Pacific Cohort Studies Collaboration
Feb 26, 2008·Circulation Journal : Official Journal of the Japanese Circulation Society·Yuji OkuraYoshifusa Aizawa
Dec 25, 2008·Circulation·Hirotsugu UeshimaTomonori Okamura
Jul 7, 2011·Circulation·Anthony S Kim, S Claiborne Johnston
Oct 4, 2011·Mayo Clinic Proceedings·Telly A MeadowsUNKNOWN REACH Registry Investigators
Jan 25, 2013·Diabetologia·Y G KimY M Cho
Jul 12, 2013·Circulation Journal : Official Journal of the Japanese Circulation Society·Jun Hata, Yutaka Kiyohara
Sep 3, 2013·The New England Journal of Medicine·Benjamin M SciricaUNKNOWN SAVOR-TIMI 53 Steering Committee and Investigators
Sep 3, 2013·The New England Journal of Medicine·William B WhiteUNKNOWN EXAMINE Investigators
Jun 9, 2015·The New England Journal of Medicine·Jennifer B GreenUNKNOWN TECOS Study Group
Sep 18, 2015·The New England Journal of Medicine·Bernard ZinmanUNKNOWN EMPA-REG OUTCOME Investigators
May 18, 2016·Journal of Diabetes Investigation·Yutaka SeinoDaisuke Yabe
Apr 22, 2017·Chest·Ying BaiGregory Y H Lip
Jun 13, 2017·The New England Journal of Medicine·Bruce NealUNKNOWN CANVAS Program Collaborative Group
Mar 16, 2018·Journal of the American College of Cardiology·Mikhail KosiborodUNKNOWN CVD-REAL Investigators and Study Group
Mar 28, 2018·Journal of Diabetes Investigation·Masakazu HanedaEiichi Araki
Aug 23, 2018·Diabetologia·Merlin C Thomas, David Z I Cherney
Oct 26, 2018·Circulation·Silvio E InzucchiBernard Zinman
Nov 13, 2018·The New England Journal of Medicine·Stephen D WiviottUNKNOWN DECLARE–TIMI 58 Investigators
Nov 13, 2018·JAMA : the Journal of the American Medical Association·Julio RosenstockUNKNOWN CARMELINA Investigators
Nov 15, 2018·Lancet·Thomas A ZelnikerMarc S Sabatine
Jan 31, 2019·Diabetes, Obesity & Metabolism·Tadashi ToyamaVlado Perkovic
Mar 4, 2019·BMJ Open·Rimei NishimuraYukio Shimasaki
Aug 31, 2019·BMJ : British Medical Journal·Björn PasternakHenrik Svanström
Nov 20, 2019·The American Journal of Cardiology·Subodh Verma
Jan 28, 2020·Circulation·Thomas A ZelnikerStephen D Wiviott
Feb 14, 2020·Cardiovascular Diabetology·Shih-Chieh ShaoEdward Chia-Cheng Lai